相关实验视频
Updated: Jul 9, 2026
10:17
The Tail Suspension Test
Published on: January 28, 2012
在阿尔茨海默病中对塔克林的受控试验. 塔克林研究小组的研究
M Farlow1, S I Gracon, L A Hershey
1Center for Alzheimer's Disease and Related Disorders, Indiana University Medical Center, Indianapolis.
JAMA
|November 11, 1992
概括
塔克林化在12周内在阿尔茨海默病患者的认知功能改善方面表现出有效性. 虽然观察到肝脏毒性,但它是可逆的,并且可以通过监测来管理.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 老年病的医生 老年病的医生
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 塔克林是一种胆酶抑制剂,研究了其在阿尔茨海默病中的治疗潜力.
研究的目的:
- 在可能患有阿尔茨海默氏症的患者中,与安慰剂相比,评估塔克林化的疗效和安全性.
- 为了确定与剂量相关的效应和治疗的临床结果.
主要方法:
- 一项为期12周的双盲,安慰剂控制,并行组研究,涉及可能患有阿尔茨海默病的门诊患者.
- 患者接受不同剂量的塔克林 (20毫克/天,40毫克/天) 或安慰剂,在第二个6周内剂量升级.
- 使用阿尔茨海默氏病评估量表 (ADAS) 的认知组成部分和临床全球变化印象 (CGIC) 评估了疗效.
主要成果:
- 塔克林治疗显示了与剂量相关的认知功能和总体印象得分的改善,在12周后显著 (ADAS认知P = .014,CGICP = .014).
- 与安慰剂相比,80 mg/d的塔克林剂量显示出显著的改善 (ADAS认知P = .015).
- 25%的患者出现了可逆的无症状转氨酶升高;还报告了恶心和胃肠道问题.
结论:
- 塔克林化在改善阿尔茨海默病的一些患者的认知功能和全球状态方面是有效的.
- 观察到的治疗效应具有临床意义,并得到医生和护理人员的认可.
- 塔克林诱导的肝毒性是可逆的,可以通过定期监测氨酸转移酶来检测.
相关概念视频
01:11Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...